Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD 21.49 million) in a Series A financing round, led by Chengdu Wenjiang Emerging Industry Venture Capital Fund Partnership Limited, Tigermed Consulting, Yingke PE, Huaxin Asset Management, and Sichuan Mansaisi Pharma.
Company Background and Pipeline
Founded in 2021, Westgene Bio has four products at clinical stages, including a novel coronavirus variant mRNA vaccine, an mRNA drug targeting EBV-related tumors, a liver cancer mRNA drug, and the new adjuvant WGa01.-Fineline Info & Tech
